The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers DFIATIM trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F25%3A00636229" target="_blank" >RIV/67985904:_____/25:00636229 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/25:00085672 RIV/00216208:11120/25:43928551 RIV/00216208:11130/25:10498417

Výsledek na webu

<a href="https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04041-0" target="_blank" >https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04041-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12866-025-04041-0" target="_blank" >10.1186/s12866-025-04041-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers DFIATIM trial

Popis výsledku v původním jazyce

Background Diabetic foot infections (DFIs) contribute to the global disability burden. Beta-lactams are the most commonly used antibiotics for treating DFIs. However, the use of antibiotics may lead to disruption of the healthy balance of the gut microbiota, causing dysbiosis. Methods Patients with infected diabetic foot ulcers (iDFUs) were treated with two kinds of beta-lactams (amoxicillin/clavulanic acid or ceftazidime) according to microbial sensitivity of causative agents via bolus or continuous administration modes. Changes in the gut microbiome of patients were analyzed. Diabetic patients without iDFUs were used as a control group. 16 S ribosomal RNA gene amplicon sequencing was performed on stool samples collected from participants.ResultsAlpha diversity and beta diversity of gut microbiota of treated patients did not show significant differences between bolus and continuous modes. However, significant differences were observed between gut microbiota diversity of treated patients and control group. PCoA plots showed individualized responses of the patient's gut microbiota to antibiotics at different times using both administration forms associated with the pre-treatment state of microbiota composition. Enterococcus, Sellimonas, and Lachnoclostridium were the common bacterial markers differentially abundant in the gut microbiota of antibiotic-treated patients with iDFUs while Roseburia, Dorea, and Monoglobus were mainly abundant in the gut microbiota of patients without iDFUs. Predicted pathways like Transporters, ABC transporters and Phosphotranspherase system (PTS) were upregulated in the gut microbiome of patients treated with bolus regime which may lead to increased intestinal barrier permeability. Conclusion The present study reported alterations in gut microbiota composition and functionality and provided the bacterial markers as well as potential metabolic signatures associated with each administration mode in patients with iDFUs, which may be used as a reference set for future studies of the effect of antibiotics administration on the gut microbiome of patients with iDFUs. This study shed light on the importance of understanding the effect of antibiotic administration form on gut microbiome in patients with iDFUs.

Název v anglickém jazyce

The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers DFIATIM trial

Popis výsledku anglicky

Background Diabetic foot infections (DFIs) contribute to the global disability burden. Beta-lactams are the most commonly used antibiotics for treating DFIs. However, the use of antibiotics may lead to disruption of the healthy balance of the gut microbiota, causing dysbiosis. Methods Patients with infected diabetic foot ulcers (iDFUs) were treated with two kinds of beta-lactams (amoxicillin/clavulanic acid or ceftazidime) according to microbial sensitivity of causative agents via bolus or continuous administration modes. Changes in the gut microbiome of patients were analyzed. Diabetic patients without iDFUs were used as a control group. 16 S ribosomal RNA gene amplicon sequencing was performed on stool samples collected from participants.ResultsAlpha diversity and beta diversity of gut microbiota of treated patients did not show significant differences between bolus and continuous modes. However, significant differences were observed between gut microbiota diversity of treated patients and control group. PCoA plots showed individualized responses of the patient's gut microbiota to antibiotics at different times using both administration forms associated with the pre-treatment state of microbiota composition. Enterococcus, Sellimonas, and Lachnoclostridium were the common bacterial markers differentially abundant in the gut microbiota of antibiotic-treated patients with iDFUs while Roseburia, Dorea, and Monoglobus were mainly abundant in the gut microbiota of patients without iDFUs. Predicted pathways like Transporters, ABC transporters and Phosphotranspherase system (PTS) were upregulated in the gut microbiome of patients treated with bolus regime which may lead to increased intestinal barrier permeability. Conclusion The present study reported alterations in gut microbiota composition and functionality and provided the bacterial markers as well as potential metabolic signatures associated with each administration mode in patients with iDFUs, which may be used as a reference set for future studies of the effect of antibiotics administration on the gut microbiome of patients with iDFUs. This study shed light on the importance of understanding the effect of antibiotic administration form on gut microbiome in patients with iDFUs.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Microbiology

ISSN

1471-2180

e-ISSN

1471-2180

Svazek periodika

25

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

15

Strana od-do

339

Kód UT WoS článku

001498532600002

EID výsledku v databázi Scopus

2-s2.0-105006833935